Dianthus Therapeutics (DNTH) Q3 2026 earnings review
Dianthus cuts nerve trial size as high response speeds schedule
Dianthus Therapeutics locked in late-stage timelines for its lead autoimmune nerve drug while its quarterly spending climbed. A 75% responder rate among the first 40 patients in its chronic nerve disorder study allowed the biotech developer to cut required Part A enrollment below 200 patients. Operating expenses rose 47% from a year ago by our math to $60 million, but $1.24 billion in cash and investments funds the business into 2030.
| CAPTIVATE Part A interim response rate | 75% 50% target hurdle |
|---|---|
| CAPTIVATE Part A projected enrollment | <200 patients cut from up to 256 previously |
| Total cash and investments | $1.24B funds operations into 2030 |
| Net loss | $46.6M +27% from a year ago |
⚖️ Verdict: 🟢 Bullish
The story got better because the high responder rate took time and risk out of the chronic nerve disorder trial. Management set firm readout dates of late 2027 for Part A and late 2028 for Part B, and chief executive Marino Garcia committed to starting a third Phase 3 trial in 2027 for multifocal motor neuropathy. One caution: the initial healthy volunteer readout for its second drug, DNTH212, slipped from late 2026 into the first quarter of 2027.
The question now is whether claseprubart can match its early chronic nerve results in next month's Phase 2 multifocal motor neuropathy readout. Strong muscle function gains would clear the way for three simultaneous Phase 3 programs, whereas weak efficacy would narrow the drug's commercial reach. Top-line data from the 46-patient MoMeNtum trial in December 2026 will decide.
🐂 Bull Case
High Response Rate Cuts Nerve Trial Enrollment
Dianthus is testing claseprubart, an injected antibody that blocks a specific immune protein, in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness. The Phase 3 CAPTIVATE trial runs an open-label first part to find patients who respond to the drug before moving them into a placebo-controlled second part.
Because 75% of the first 40 patients responded to treatment—above the 50% threshold—the trial is "now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders". At the end of 2025, management had planned to enroll up to 256 patients, so the higher response rate cuts required Part A enrollment by more than a fifth by our math.
Fewer patients in Part A allowed the biotech company to set firm readout dates ahead of its year-end schedule. Management now expects top-line results from Part A by the end of 2027 and final Part B results by the end of 2028, with no drug-related serious infections or lupus symptoms seen so far.
What to watch: Full Part A top-line results by the end of 2027. Keeping the response rate near 75% across all enrolled patients would confirm that claseprubart works broadly in CIDP before the final withdrawal readout.
Dianthus Commits to a Third Late-Stage Trial
Multifocal motor neuropathy (MMN) is a rare nerve disease that causes progressive muscle weakness and currently has only one approved therapy, intravenous immunoglobulin. Chief executive Marino Garcia wants claseprubart to replace those long infusions with a two-milliliter injection that patients give themselves every two weeks.
"Following top-line results from our Phase 2 MoMeNtum trial of claseprubart in December, we plan to quickly initiate a Phase 3 trial in MMN in 2027." Patient demand pushed enrollment in the Phase 2 study to 46 participants, beating the original target of 36. Starting a Phase 3 MMN study in 2027 will give the autoimmune drug developer three simultaneous late-stage trials for the same drug, alongside its ongoing studies in CIDP and generalized myasthenia gravis (gMG), an autoimmune muscle weakness condition.
What to watch: Top-line data from the 46 patients in the Phase 2 MoMeNtum study in December 2026. Clear muscle strength improvements over placebo will validate starting the Phase 3 trial next year.
Over $1.2 Billion Funds Operations Into 2030
Running three Phase 3 trials at the same time while advancing early-stage drugs requires a large balance sheet. Following its March stock offering, Dianthus ended September with $1.24 billion in cash, cash equivalents and investments by our math, up $53.4 million from the second quarter.
That cash pile earned $12.1 million in interest and investment income during the third quarter, more than triple the $3.7 million earned a year ago. Interest income covered a fifth of the quarter's total operating expenses. As a result, the company expects its existing cash to fund operations into 2030, well past the 2028 readout dates for all three late-stage claseprubart studies.
What to watch: Quarterly cash and investments balance in the fourth-quarter report. It will show whether new trial startup costs begin to draw down the $1.24 billion reserve.
🐻 Bear Case
Early Lupus Drug Readout Slips Into 2027
Beyond claseprubart, Dianthus is developing DNTH212, a dual-action protein designed to treat rheumatology disorders like systemic lupus erythematosus (SLE), an autoimmune disease that attacks multiple organs. Partner Leads Biolabs is running a two-part Phase 1 trial in China testing single doses in healthy volunteers first and then in lupus patients.
While "dosing of SLE patients in Part B of the Phase 1 SAD study was initiated in October", the initial readout for healthy volunteers in Part A slipped by a quarter. Management now expects preliminary Part A data in the first quarter of 2027, whereas the second-quarter release promised that data by the end of 2026. Preliminary lupus patient data from Part B and from a separate multi-dose study outside China will not arrive until the second half of 2027.
What to watch: Preliminary Phase 1 Part A healthy volunteer data in the first quarter of 2027. The results will test whether DNTH212 safely suppresses its two immune targets in humans without further schedule delays.
Rising Trial Costs and Dilution Drive Per-Share Math
On the surface, Dianthus reported a smaller per-share loss of $0.81 in the third quarter, compared with $0.97 a year earlier. However, the actual net loss widened by 26.9% by our math, rising from $36.8 million to $46.6 million as the clinical pipeline expanded.
- Research and development spending: $45.6 million, up 40.4% from a year ago by our math
- General and administrative spending: $14.1 million, up 71.8% from a year ago by our math
- Weighted-average shares and pre-funded warrants: 57.3 million, up 51.7% from a year ago by our math
Research spending rose "driven by higher clinical costs and increased headcount to support claseprubart Phase 2 and Phase 3 development", alongside work on DNTH212 and DNTH312, a third preclinical autoimmune drug. The per-share loss shrank only because the March financing increased the share count by more than half. Launching the Phase 3 MMN study and a multi-dose DNTH212 trial in 2027 will push quarterly operating expenses higher.
What to watch: Research and development expenses in the first half of 2027 as the Phase 3 MMN study and the Phase 1 multi-dose DNTH212 trial begin dosing patients.
👓 Other Themes
Bond Market Moves Create Paper Losses on Cash Pile
Because Dianthus holds $1.19 billion of its reserve in short-term and long-term marketable investments, bond market fluctuations directly affect its comprehensive income. In the third quarter, the biotech group recorded an unrealized loss on marketable securities of $4.1 million, bringing the nine-month unrealized loss to $6.8 million, though interest income still added $12.1 million in the quarter.
💲 Other KPIs
Non-cash employee stock pay more than doubled from $5.8 million a year ago, rising 119.0% by our math as the company hired more staff. Stock grants reached $6.3 million in research and $6.4 million in administration, accounting for 45.5% of total general and administrative expenses this quarter.
Total deferred revenue—upfront license payments received for work not yet completed—fell 5.8% from $7.47 million last quarter by our math. The balance declined as Dianthus recognized $1.21 million in license revenue on its income statement during the third quarter, up from $0.76 million in the second quarter.
🔮 Guidance
New. The developer issued its first completion target for the open-label portion of its CIDP nerve study, aiming for top-line results by the end of 2027. Strong responder rates in the first 40 patients allowed management to cap required Part A enrollment below 200 patients, down from up to 256 previously.
Raised. Management delivered the timeline for the 128-patient placebo-controlled withdrawal phase a quarter ahead of its year-end 2026 promise, setting the readout for the end of 2028. That puts both Phase 3 registrational readouts for claseprubart in CIDP and gMG in the second half of 2028.
Unchanged. Top-line results from the 46-patient placebo-controlled study of claseprubart in multifocal motor neuropathy remain on schedule for next month.
New. Following the December 2026 readout of the Phase 2 MoMeNtum study, the company plans to start a Phase 3 registrational trial in MMN during 2027.
Unchanged. The registrational study testing two-week and four-week subcutaneous dosing of claseprubart in generalized myasthenia gravis began in June and remains on track for results in the second half of 2028.
Cut. Preliminary healthy volunteer data from the single ascending dose study in China moved back from year-end 2026 to the first quarter of 2027. It is the second minor schedule shift after the first-quarter release targeted the second half of 2026.
New. After dosing the first lupus patient in October 2026, management set its first readout target for Part B patient data in the second half of 2027.
New. Dianthus will run its own multiple ascending dose trial in healthy volunteers outside China starting in the second quarter of 2027, with preliminary results due in the second half of 2027.
New. The biotech firm plans to outline next clinical steps for DNTH212 in Sjögren's disease, lupus, and dermatomyositis by the end of 2027.
Unchanged. The internally developed dual-target protein combining claseprubart and TACI remains on schedule to be ready for human trials by the end of 2027.
Unchanged. Management projects that its $1.24 billion in cash and investments will fund planned operations and late-stage clinical trials into 2030.
❓ Key Questions
Why did healthy volunteer data for DNTH212 slip to 2027?
Part B dosing in lupus patients already started in October based on early safety reads, yet the Part A healthy volunteer readout moved from late 2026 to the first quarter of 2027. Did partner Leads Biolabs add extra dose cohorts?
What caused total cash to rise $53 million this quarter?
Cash and investments climbed by $53.4 million from June despite a $46.6 million net loss, and the release omits a cash flow statement. Did the company raise money through an at-the-market stock program or warrant exercises?
What will the Phase 3 MMN trial design look like?
Chief executive Marino Garcia plans to start a Phase 3 study in multifocal motor neuropathy in 2027 after December's Phase 2 readout. How many patients and which dosing intervals will the FDA require for registration?